Cyramza fails to improve overall survival in gastric cancer, Lilly scraps regulatory plans

Eli Lilly has unveiled Phase 3 results which reveal that its VEGF Receptor 2 antagonist Cyramza (ramucirumab) met its primary endpoint of progression-free survival (PFS) when used in combination with cisplatin and capecitabine or 5-FU (5-fluorouracil) as a first-line treatment of patients with HER2-negative metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma. However, despite this, the treatment failed to improve overall survival (OS), and as a result Lilly will not be looking to file for regulatory approval in this indication.

read more

Original Article: Cyramza fails to improve overall survival in gastric cancer, Lilly scraps regulatory plans

More From BioPortfolio on "Cyramza fails to improve overall survival in gastric cancer, Lilly scraps regulatory plans"

• Related Companies
• Related Events
• Related Clinical Trials
• Related PubMed Entries
• Related Medications